JP5996438B2 - 抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法 - Google Patents

抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法 Download PDF

Info

Publication number
JP5996438B2
JP5996438B2 JP2012549690A JP2012549690A JP5996438B2 JP 5996438 B2 JP5996438 B2 JP 5996438B2 JP 2012549690 A JP2012549690 A JP 2012549690A JP 2012549690 A JP2012549690 A JP 2012549690A JP 5996438 B2 JP5996438 B2 JP 5996438B2
Authority
JP
Japan
Prior art keywords
antibody
disease
test
chronic inflammatory
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012549690A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012086346A1 (ja
Inventor
康広 三宅
康広 三宅
和秀 山本
和秀 山本
松本 和幸
和幸 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Okayama University NUC
Original Assignee
Okayama University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Okayama University NUC filed Critical Okayama University NUC
Publication of JPWO2012086346A1 publication Critical patent/JPWO2012086346A1/ja
Application granted granted Critical
Publication of JP5996438B2 publication Critical patent/JP5996438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012549690A 2010-12-22 2011-11-17 抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法 Expired - Fee Related JP5996438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010286456 2010-12-22
JP2010286456 2010-12-22
PCT/JP2011/076507 WO2012086346A1 (fr) 2010-12-22 2011-11-17 Méthode de diagnostic pour des maladies inflammatoires chroniques à l'aide d'un anticorps contre des molécules co-stimulatrices inhibitrices en tant que marqueur

Publications (2)

Publication Number Publication Date
JPWO2012086346A1 JPWO2012086346A1 (ja) 2014-05-22
JP5996438B2 true JP5996438B2 (ja) 2016-09-21

Family

ID=46313628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549690A Expired - Fee Related JP5996438B2 (ja) 2010-12-22 2011-11-17 抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法

Country Status (2)

Country Link
JP (1) JP5996438B2 (fr)
WO (1) WO2012086346A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
CN113454462A (zh) * 2019-02-20 2021-09-28 株式会社合伙企业 固相反应芯片和使用该固相反应芯片的测定方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012009200; 松井利浩: '自己免疫疾患における抗CTLA-4(CD152)自己抗体とその意義' 臨床免疫 Vol.35,No.1, 20010125, P.95-101 *
JPN6012009201; 岡崎拓、岡崎一美: 'PD-1分子による免疫応答の制御' 月刊メディカル・サイエンス・ダイジェスト Vol.36,No.12, 20101125, P.1081-1084 *
JPN6012009202; 小谷素子: '自己免疫疾患の発症における補助シグナルの役割' Mol.Med. Vol.39,No.10, 200210, P.1142-1148 *
JPN6012009203; 加藤智啓: 'リンパ球表面分子に対する新しい自己抗体とその臨床的意義' 炎症と免疫 Vol.10,No.3, 200205, P.315-319 *
JPN6012009204; 平出綾子ほか: '自己免疫性肝炎患者における末梢リンパ球抑制性マーカーの検討' 肝臓 Vol.52,No.Supplement2, 20110910, P.A673 *

Also Published As

Publication number Publication date
WO2012086346A1 (fr) 2012-06-28
JPWO2012086346A1 (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
Sah et al. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis
Sutherland et al. Review of fecal biomarkers in inflammatory bowel disease
Benzimra et al. Acute rejection
Levitsky et al. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure
Nesher et al. Anti-nuclear envelope antibodies: Clinical associations
US20120295814A1 (en) CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
JP2016515215A (ja) ドナー特異的抗体を検出する方法及び該方法を実施するためのシステム
Alunno et al. Interferon gamma-inducible protein 16 in primary Sjögren’s syndrome: a novel player in disease pathogenesis?
Xibing et al. Relationship between HBV genotypes B, C and follicular helper T cells in patients with chronic hepatitis B and its significance
WO2011129382A1 (fr) Procédés et réactifs pour diagnostiquer la polyarthrite rhumatoïde
Gandini et al. Diagnosing coeliac disease: A literature review
Rathinam et al. Immunological tests and their interpretation in uveitis
Lindenberg et al. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis
Tangermann et al. Low sensitivity of simtomax point of care test in detection of celiac disease in a prospective Multicenter Study
JP5996438B2 (ja) 抑制性補助刺激分子に対する抗体をマーカーとする慢性炎症性疾患の検査方法
Wiik Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes
JP6876301B2 (ja) 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
Forcione et al. New kid on the block? Autoimmune pancreatitis
WO2015155513A1 (fr) Diagnostic du cancer par détection d'il-18 dimérique
US20220276243A1 (en) Inflammatory bowel disease diagnosis method, diagnosis probe and diagnosis kit
Lidman Clinical Diagnosis in Patients with Smooth Muscle Antibodies: A Study of a One‐year Material
Bogdanos et al. Specificity of anti‐sp100 antibody for primary biliary cirrhosis
Allawi et al. Role of Anti-Nucleosome Antibodies in Diagnosis and Evaluation of both Disease Activity and Response to Therapy in Lupus Nephritis
Jois et al. Enzyme inhibitory antibody to pyruvate dehydrogenase: diagnostic utility in primary biliary cirrhosis
CN113624977A (zh) SARS-CoV-2感染诊断方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160824

R150 Certificate of patent or registration of utility model

Ref document number: 5996438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees